Addex Stock Soars on Crucial Update From Indivior Research Deal

Zacks08-28

Shares of Addex Therapeutics ADXN soared 54.6% after the company announced the selection of clinical candidates from the GABAB positive allosteric modulator (PAM) research collaboration with Indivior ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2463496525?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","is_english":true,"pubTime":"2024-08-28 22:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2463496525","market":"us","top_or_hot":-1,"title":"Addex Stock Soars on Crucial Update From Indivior Research Deal","media":"Zacks","content":"<div>\n<p>Shares of Addex Therapeutics ADXN soared 54.6% after the company announced the selection of clinical candidates from the GABAB positive allosteric modulator (PAM) research collaboration with Indivior ...</p>\n\n<a href=\"https://finance.yahoo.com/news/addex-stock-soars-crucial-indivior-143000320.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Addex Stock Soars on Crucial Update From Indivior Research Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAddex Stock Soars on Crucial Update From Indivior Research Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-28 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/addex-stock-soars-crucial-indivior-143000320.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Addex Therapeutics ADXN soared 54.6% after the company announced the selection of clinical candidates from the GABAB positive allosteric modulator (PAM) research collaboration with Indivior ...</p>\n\n<a href=\"https://finance.yahoo.com/news/addex-stock-soars-crucial-indivior-143000320.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1430594728.SGD","symbol_name":"Eastspring Investments - Global Low Volatility Equity AS SGD","start_time":0,"source_url":"https://finance.yahoo.com/news/addex-stock-soars-crucial-indivior-143000320.html","article_id":"2463496525","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2463496525","pubTimestamp":1724855400,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Per the press release, Indivior has chosen a compound for future development in treating substance use disorder and will manage all further development efforts. Under the terms of the existing agreement, Addex is eligible to receive up to $330 million if certain regulatory, clinical and commercial milestones are met, along with tiered royalties on net sales from INDV, ranging from high single digits to low double digits. Subject to successful development, such payments will aid ADXN in strengthening in cash position as it continues to build its portfolio of novel treatments for neurological disorders.Year to date, shares of Addex have rallied 91.4% against the industry’s 1% decline.Indivior stated that the distinguished mechanism of its selected substance use disorder treatment candidate could help overcome the complex challenges in this field to potentially develop new therapies. INDV expects to begin investigational new drug application  enabling studies of the candidate in the first","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4081":"电力公用事业","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4588":"碎股","ADXN":"Addex Therapeutics Ltd","JNJ":"强生","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","FULC":"Fulcrum Therapeutics","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","BK4581":"高盛持仓","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","BK4504":"桥水持仓","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4563":"昨日强势股","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","BK4592":"伊斯兰概念","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","PAM":"Pampa Energia S.A.","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","INDV":"INDIVIOR PLC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H"},"translate_title":"Addex股价因Indivior Research交易的重要更新而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAM":1,"ADXN":1,"JNJ":1,"INDV":1,"FULC":0.9},"content_text":"Shares of Addex Therapeutics ADXN soared 54.6% after the company announced the selection of clinical candidates from the GABAB positive allosteric modulator (PAM) research collaboration with Indivior PLC INDV.\nAddex & Indivior Research Deal Update\nPer the press release, Indivior has chosen a compound for future development in treating substance use disorder and will manage all further development efforts. Under the terms of the existing agreement, Addex is eligible to receive up to $330 million if certain regulatory, clinical and commercial milestones are met, along with tiered royalties on net sales from INDV, ranging from high single digits to low double digits. Subject to successful development, such payments will aid ADXN in strengthening in cash position as it continues to build its portfolio of novel treatments for neurological disorders.\nYear to date, shares of Addex have rallied 91.4% against the industry’s 1% decline.\nImage Source: Zacks Investment Research\nIndivior stated that the distinguished mechanism of its selected substance use disorder treatment candidate could help overcome the complex challenges in this field to potentially develop new therapies. INDV expects to begin investigational new drug application (IND) enabling studies of the candidate in the first half of 2025.\nAdditionally, Addex has exercised its option to select a compound to further develop its independent GABAB PAM program to treat chronic cough. ADXN also expects to initiate IND-enabling studies for its candidate in 2025.\nAddex’s Setback on Failure of Partner-Sponsored Epilepsy Drug Study\nThis significant development in the collaboration agreement with Indivior comes at a crucial time after Addex faced a major setback last month. Its other partner, J&J JNJ, informed the company that it has discontinued the development of the investigational candidate, ADX71149 (JNJ-40411813), in epilepsy. \nIn the absence of a marketed product, Addex only earns revenues from its ongoing collaborations. If the JNJ collaboration comes to an end, the company will lose a significant portion of its revenues, which could lead to a shortage of cash to fund developmental activities.\nJ&J’s decision to discontinue the epilepsy study was based on disappointing results from the mid-stage study of ADX71149. Per the data readout, the candidate, in combination with standard of care treatment in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam, failed to achieve the primary endpoint of statistically significant time for patients to reach baseline seizure count.\nAlthough the collaboration remains ongoing until the totality of the phase II epilepsy data is analyzed, it is likely that the partnership with JNJ will soon dissolve once the same is complete.\n\nAddex Therapeutics Ltd. Sponsored ADR Price and Consensus\n\nAddex Therapeutics Ltd. Sponsored ADR price-consensus-chart | Addex Therapeutics Ltd. Sponsored ADR Quote\n\nZacks Rank & Other Stock to Consider\nAddex currently carries a Zacks Rank #2 (Buy).\nAnother top-ranked stock in the overall drug/biotech sector includes Fulcrum Therapeutics FULC, sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, the consensus estimate for Fulcrum Therapeutics’ 2024 loss per share has narrowed from $1.24 to 48 cents. The loss estimate for 2025 has narrowed from $1.71 to $1.51 during the same period. Year to date, shares of Fulcrum Therapeutics have jumped 31.3%.\nFULC beat estimates in each of the last four quarters, delivering an average earnings surprise of 393.18%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nJohnson & Johnson (JNJ) : Free Stock Analysis Report\nFulcrum Therapeutics, Inc. (FULC) : Free Stock Analysis Report\nAddex Therapeutics Ltd. Sponsored ADR (ADXN) : Free Stock Analysis Report\nIndivior PLC (INDV) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2463496525"}